Key result
Prasugrel reduces post-PCI ischemic events vs clopidogrel in ACS but increases maintenance-phase major bleeding.
RCT
Randomized
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“It would be superficial to regard this as an overall negative result. It's absolutely correct to say the primary end point didn't show a statistically significant difference between prasugrel and clopidogrel in those ACS patients managed medically, but there are several fascinating and potentially important observations.”
“Ultimately, deciding which drug is preferable will be a matter of individual clinical judgment. The FDA made sure that prasugrel's label clearly articulates the balance between efficacy and risk--a balance that physicians will need to assess carefully when choosing treatment for individual patients.”
“This recommendation is very welcome as it offers clinicians a wider choice to protect acute coronary syndrome patients against atherothrombotic events when undergoing PCI. It is important that all suitable treatment options are available so the most appropriate clinical decision to manage patients can be made particularly for higher-risk patients with other co-morbidities, such as diabetes.”
Randomized trial demonstrates reduced ischemic events with prasugrel in acute coronary syndromes, indicating sustained early and long-term protection.
OBJECTIVES: We evaluated the relative contributions of the loading and maintenance doses of prasugrel on events in a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. BACKGROUND: Prasugrel is superior to clopidogrel in preventing ischemic events in patients with an acute coronary syndrome who are undergoing percutaneous coronary intervention, but it is associated with an increased risk of major bleeding. METHODS: Landmark analyses for efficacy, safety, and net clinical benefit were performed from randomization to day 3 and from day 3 to the end of the trial. RESULTS: Significant reductions in ischemic events, including myocardial infarction, stent thrombosis, and urgent target vessel revascularization, were observed with the use of prasugrel both during the first 3 days and from 3 days to the end of the trial. Thrombolysis In Myocardial Infarction major non-coronary artery bypass graft bleeding was similar to clopidogrel during the first 3 days but was significantly greater with the use of prasugrel from 3 days to the end of the study. Net clinical benefit significantly favored prasugrel both early and late in the trial. CONCLUSIONS: Both the loading dose and maintenance dose of prasugrel were superior to clopidogrel for the reduction of ischemic events. This result emphasizes the importance of maintaining high levels of inhibition of platelet aggregation via P2Y(12) receptor inhibition, not only for the prevention of periprocedural ischemic events but also during long-term follow-up. The excess major bleeding observed with the use of prasugrel occurred predominantly during the maintenance phase. Approaches to reduce the relative excess of bleeding with prasugrel should focus on the maintenance dose (e.g., reduction in maintenance dose in previously reported high-risk subgroups, such as the elderly and those patients with low body weight). (A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention; NCT00097591).
No takes yet. Share an insight, caveat, or question.
Antman et al. (2008) conducted an RCT in Acute Coronary Syndromes. Prasugrel vs. Clopidogrel was evaluated on Ischemic events (including myocardial infarction, stent thrombosis, and urgent target vessel revascularization). Prasugrel was superior to clopidogrel for reducing ischemic events both early and late after PCI in ACS patients, but increased major bleeding predominantly during the maintenance phase.
Synapse has enriched 10 related papers. Consider them for comparative context: